Skip to main content
Top
Published in: Pituitary 3/2016

01-06-2016

Diagnosis and management of acromegaly: the patient’s perspective

Authors: Ilonka Kreitschmann-Andermahr, Sonja Siegel, Bernadette Kleist, Johannes Kohlmann, Daniel Starz, Rolf Buslei, Maria Koltowska-Häggström, Christian J. Strasburger, Michael Buchfelder

Published in: Pituitary | Issue 3/2016

Login to get access

Abstract

Purpose

Early diagnosis is a success factor for the prevention of long-term comorbidity and premature death in patients with acromegaly, but large-scale data on the diagnostic process and disease management are scarce. Therefore, we aimed to evaluate the diagnostic process, implementation of treatment and changes in life situation in patients with acromegaly, focusing on sex-specific differences.

Methods

Non-interventional patient-reported outcome study. 165 patients with clinically and biochemically proven acromegaly were questioned about the diagnostic process and utilization of health care by means of a self-developed standardized postal survey including questions on acromegaly symptoms experienced before diagnosis, number and specialty of consulted doctors, time to diagnosis and aftercare.

Results

The diagnostic process took 2.9 (SD 4.53) years, during which 3.4 (SD 2.99) physicians were consulted. Women waited longer [4.1 (SD 5.53) years] than men [1.6 (SD 2.69) years; p = 0.001] for the correct diagnosis, and consulted more doctors in the process [4.0 (SD 2.99) vs. 2.7 (SD 2.84) doctors, p < 0.001, respectively]. In 48.5 % of patients, acromegaly was diagnosed by an endocrinologist (men: 45.1 %; women: 52.4 %). Overall disease duration from symptom onset until last surgery was 5.5 (SD 6.85) years, with no sex differences. A change in employment status was the most commonly reported event after diagnosis and a quarter of the patients stated that the illness had changed their lives.

Conclusions

Our findings confirm the urgent need to increase awareness of the clinical manifestation of acromegaly to facilitate an earlier diagnosis of the disease and to provide diagnostic equality across the sexes.
Literature
5.
go back to reference Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41(1):95–102CrossRef Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41(1):95–102CrossRef
6.
go back to reference Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A (2008) Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 93(6):2035–2041. doi:10.1210/jc.2007-2149 CrossRefPubMed Nachtigall L, Delgado A, Swearingen B, Lee H, Zerikly R, Klibanski A (2008) Changing patterns in diagnosis and therapy of acromegaly over two decades. J Clin Endocrinol Metab 93(6):2035–2041. doi:10.​1210/​jc.​2007-2149 CrossRefPubMed
8.
go back to reference Keskin FE, Yetkin DO, Ozkaya HM, Haliloglu O, Sadri S, Gazioglu N, Tanriover N, Ak H, Hatipoglu E, Kadioglu P (2015) The problem of unrecognized acromegaly: surgeries patients undergo prior to diagnosis of acromegaly. J Endocrinol Invest. doi:10.1007/s40618-015-0245-3 PubMed Keskin FE, Yetkin DO, Ozkaya HM, Haliloglu O, Sadri S, Gazioglu N, Tanriover N, Ak H, Hatipoglu E, Kadioglu P (2015) The problem of unrecognized acromegaly: surgeries patients undergo prior to diagnosis of acromegaly. J Endocrinol Invest. doi:10.​1007/​s40618-015-0245-3 PubMed
9.
go back to reference Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 72(2):203–208. doi:10.1111/j.1365-2265.2009.03626.x CrossRef Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 72(2):203–208. doi:10.​1111/​j.​1365-2265.​2009.​03626.​x CrossRef
10.
go back to reference Roset M, Merino-Montero S, Luque-Ramirez M, Webb SM, Lopez-Mondejar P, Salinas I, Soto A, Bernal C, Villabona C, De Luis D, Donnay S, Pascual H, Perez-Luis J (2012) Cost of clinical management of acromegaly in Spain. Clin Drug Investig 32(4):235–245. doi:10.2165/11599680-000000000-00000 CrossRefPubMed Roset M, Merino-Montero S, Luque-Ramirez M, Webb SM, Lopez-Mondejar P, Salinas I, Soto A, Bernal C, Villabona C, De Luis D, Donnay S, Pascual H, Perez-Luis J (2012) Cost of clinical management of acromegaly in Spain. Clin Drug Investig 32(4):235–245. doi:10.​2165/​11599680-000000000-00000 CrossRefPubMed
13.
14.
go back to reference Ciresi A, Amato MC, Pivonello R, Nazzari E, Grasso LF, Minuto F, Ferone D, Colao A, Giordano C (2013) The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 98(1):E51–E59. doi:10.1210/jc.2012-2896 CrossRefPubMed Ciresi A, Amato MC, Pivonello R, Nazzari E, Grasso LF, Minuto F, Ferone D, Colao A, Giordano C (2013) The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 98(1):E51–E59. doi:10.​1210/​jc.​2012-2896 CrossRefPubMed
15.
go back to reference Colao A, Amato G, Pedroncelli AM, Baldelli R, Grottoli S, Gasco V, Petretta M, Carella C, Pagani G, Tambura G, Lombardi G (2002) Gender- and age-related differences in the endocrine parameters of acromegaly. J Endocrinol Invest 25(6):532–538CrossRefPubMed Colao A, Amato G, Pedroncelli AM, Baldelli R, Grottoli S, Gasco V, Petretta M, Carella C, Pagani G, Tambura G, Lombardi G (2002) Gender- and age-related differences in the endocrine parameters of acromegaly. J Endocrinol Invest 25(6):532–538CrossRefPubMed
16.
go back to reference Sucunza N, Barahona MJ, Resmini E, Fernandez-Real JM, Farrerons J, Lluch P, Puig T, Wagner AM, Ricart W, Webb SM (2008) Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. Eur J Endocrinol 159(6):773–779. doi:10.1530/eje-08-0449 CrossRefPubMed Sucunza N, Barahona MJ, Resmini E, Fernandez-Real JM, Farrerons J, Lluch P, Puig T, Wagner AM, Ricart W, Webb SM (2008) Gender dimorphism in body composition abnormalities in acromegaly: males are more affected than females. Eur J Endocrinol 159(6):773–779. doi:10.​1530/​eje-08-0449 CrossRefPubMed
17.
18.
go back to reference Deveugele M, Derese A, van den Brink-Muinen A, Bensing J, De Maeseneer J (2002) Consultation length in general practice: cross sectional study in six European countries. BMJ 325(7362):472CrossRefPubMedPubMedCentral Deveugele M, Derese A, van den Brink-Muinen A, Bensing J, De Maeseneer J (2002) Consultation length in general practice: cross sectional study in six European countries. BMJ 325(7362):472CrossRefPubMedPubMedCentral
21.
go back to reference Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, Jervis P, Roldan P, Mendoza V, Lopez-Felix B, Guinto G (2014) Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 99(12):4438–4446. doi:10.1210/jc.2014-2670 CrossRefPubMed Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, Jervis P, Roldan P, Mendoza V, Lopez-Felix B, Guinto G (2014) Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 99(12):4438–4446. doi:10.​1210/​jc.​2014-2670 CrossRefPubMed
22.
go back to reference Vallette S, Ezzat S, Chik C, Ur E, Imran SA, Van Uum S, Rivera J, Caspar-Bell G, Serri O (2013) Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol (Oxf) 79(1):79–85. doi:10.1111/cen.12112 CrossRef Vallette S, Ezzat S, Chik C, Ur E, Imran SA, Van Uum S, Rivera J, Caspar-Bell G, Serri O (2013) Emerging trends in the diagnosis and treatment of acromegaly in Canada. Clin Endocrinol (Oxf) 79(1):79–85. doi:10.​1111/​cen.​12112 CrossRef
24.
go back to reference Di Cecco R, Patel U, Upshur RE (2002) Is there a clinically significant gender bias in post-myocardial infarction pharmacological management in the older (>60) population of a primary care practice? BMC Fam Pract 3:8CrossRefPubMedPubMedCentral Di Cecco R, Patel U, Upshur RE (2002) Is there a clinically significant gender bias in post-myocardial infarction pharmacological management in the older (>60) population of a primary care practice? BMC Fam Pract 3:8CrossRefPubMedPubMedCentral
26.
go back to reference Chapman KR, Tashkin DP, Pye DJ (2001) Gender bias in the diagnosis of COPD. Chest 119(6):1691–1695CrossRefPubMed Chapman KR, Tashkin DP, Pye DJ (2001) Gender bias in the diagnosis of COPD. Chest 119(6):1691–1695CrossRefPubMed
27.
go back to reference Hawker GA, Wright JG, Coyte PC, Williams JI, Harvey B, Glazier R, Wilkins A, Badley EM (2001) Determining the need for hip and knee arthroplasty: the role of clinical severity and patients’ preferences. Med Care 39(3):206–216CrossRefPubMed Hawker GA, Wright JG, Coyte PC, Williams JI, Harvey B, Glazier R, Wilkins A, Badley EM (2001) Determining the need for hip and knee arthroplasty: the role of clinical severity and patients’ preferences. Med Care 39(3):206–216CrossRefPubMed
28.
go back to reference Kreitschmann-Andermahr I, Psaras T, Tsiogka M, Starz D, Kleist B, Siegel S, Milian M, Kohlmann J, Menzel C, Fuhrer-Sakel D, Honegger J, Sure U, Muller O, Buchfelder M (2015) From first symptoms to final diagnosis of Cushing’s disease: experiences of 176 patients. Eur J Endocrinol 172(3):285–289. doi:10.1530/eje-14-0766 CrossRefPubMed Kreitschmann-Andermahr I, Psaras T, Tsiogka M, Starz D, Kleist B, Siegel S, Milian M, Kohlmann J, Menzel C, Fuhrer-Sakel D, Honegger J, Sure U, Muller O, Buchfelder M (2015) From first symptoms to final diagnosis of Cushing’s disease: experiences of 176 patients. Eur J Endocrinol 172(3):285–289. doi:10.​1530/​eje-14-0766 CrossRefPubMed
29.
go back to reference Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148. doi:10.1210/jc.2009-2670 CrossRefPubMed Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95(7):3141–3148. doi:10.​1210/​jc.​2009-2670 CrossRefPubMed
30.
32.
go back to reference Schofl C, Grussendorf M, Honegger J, Tonjes A, Thyroke-Gronostay D, Mayr B, Schopohl J (2015) Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey. Eur J Endocrinol 172(4):351–356. doi:10.1530/eje-14-0844 CrossRefPubMed Schofl C, Grussendorf M, Honegger J, Tonjes A, Thyroke-Gronostay D, Mayr B, Schopohl J (2015) Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey. Eur J Endocrinol 172(4):351–356. doi:10.​1530/​eje-14-0844 CrossRefPubMed
Metadata
Title
Diagnosis and management of acromegaly: the patient’s perspective
Authors
Ilonka Kreitschmann-Andermahr
Sonja Siegel
Bernadette Kleist
Johannes Kohlmann
Daniel Starz
Rolf Buslei
Maria Koltowska-Häggström
Christian J. Strasburger
Michael Buchfelder
Publication date
01-06-2016
Publisher
Springer US
Published in
Pituitary / Issue 3/2016
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-015-0702-1

Other articles of this Issue 3/2016

Pituitary 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.